



03 CO

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ellen M BEASLEY et al. Art Unit:

Serial No.: 09/867,570 Examiner:

Filed: May 31, 2000 Atty. Docket: CL000900CIP

For: ISOLATED HUMAN G-PROTEIN COUPLED
RECEPTORS, NUCLEIC ACID MOLECULES ENCODING
HUMAN GPCR PROTEINS, AND USES THEREOF

**Statement Regarding Duty to Disclose Information Material To Patentability Under
37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

The undersigned states that each item listed on the attached PTO Form SB/08A was first cited in a communication from a Foreign Patent Office in the above application's foreign counterpart or not known to the Undersigned for more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

CELERA GENOMICS

Date: July 1, 2002

By:


Lin Sun-Hoffman, Ph.D., Reg No. 47,983

Celera Genomics Corporation
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Tel: 240-453-3628
Fax: 240-453-3084

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

<i>Complete if Known</i>	
Application Number	09/867,570
Filing Date	May 31, 2001
First Named Inventor	Ellen M. BEASLEY et al.
Art Unit	
Examiner Name	
Attorney Docket Number	CL000900CIP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear Type
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)			
	1	WO 00/40724 A	07-13-2000	Lexicon Genetics, Inc.	SEQ ID: 1&2
	2	WO 99/32519 A	07-01-1999	Fortin Yves et al.	SEQ ID: 3&4
	3	WO 01/36471 A	05-25-2001	Arena Pharmaceuticals, Inc. et al.	SEQ ID: 19&20
	4	WO 00/2456 A	04-13-2000	Fukusumi Shoji et al.	SEQ ID: 1&2
	5	WO 00/20455 A	04-13-2000	Matsui Hideki et al.	SEQ ID: 1-4
	6	WO 01/48189 A	07-05-2001	Matsuhashi Shun Ichiro	SEQ ID: 7&15
	7	WO 01/74902 A	10-11-2001	Baggerman Geert Luc Elisabeth	SEQ ID: 4,6&9
	8	WO 01/83555 A	11-08-2001	Dong Zinzhong et al.	SEQ ID: 15, 16, 30-33

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

O I P E
JUL 01 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/867,570
Filing Date	May 31, 2001
First Named Inventor	Ellen M. BEASLEY et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	CL000900CIP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	9	DATABASE EMBL: "Homo sapiens chromosome 11 clone rP11-583F24 map 11." 02-14-2000: Database accession no. AC023078	X
	10	DATABASE EMBL: "Homo sapiens chromosome 20 clone RP11-206C1." 01-06-2000: Database accession no. AC20568	
	11	STADEL J M et al.: "Orpahn G Protein-Coupled Receptors: a neglected opportunity for pioneer drug discovery." Trends in Pharmacological Sciences, Elsevier Trends Journal, Cambridge, GB, vol 18, no 11, pages 430-437; 11-01-1997	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.